Absci Corporation
HealthcareNASDAQ:ABSI · NASDAQ Global Select
+$0.29 today
Vol 4.42M · Avg 4.88M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-60.8%
avg -36.0%
ROIC
-63.6%
avg -40.7%
ROA
-53.3%
avg -37.0%
Analysis
ROA is currently the strongest return metric at -53.3% versus its period average of -37.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Sean McClain | Founder, Chief Executive Officer, President & Director | $1.08M | — | 36 | $8.72M | 5.59% |
Zachariah Jonasson | Chief Business Officer & Chief Financial Officer | $816,507.00 | — | 53 | $491,464.00 | 0.32% |
Amer-Denis Akkad | Vice President of Research | — | — | — | — | — |
Amir Shanehsazzadeh | Chief AI Officer | — | — | — | — | — |
Shelby Walker | Chief Legal Officer | — | — | 51 | $139,775.00 | 0.09% |
Christine Lemke | Senior Vice President of Portfolio & Growth Strategy | — | — | — | — | — |
Anders Kassow | Head of Intellectual Property | — | — | — | — | — |
Ransi Somaratne FACC | Chief Medical Officer | — | — | 60 | — | — |
Melissa Patterson | Chief of Staff | — | — | — | — | — |
Alexander Khan | CVP of Finance & Head of Investor Relations | — | — | — | — | — |
Todd Bedrick | Senior Vice President & Chief Accounting Officer | — | — | — | $216,942.00 | 0.14% |
Jeanne Schreuder SPHR | Senior Vice President of People & Experience | — | — | — | — | — |
Wen Sha | Chief of Staff | — | — | — | — | — |
Karin Wierinck | Chief People Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$1.22M
Sells
2
$132,328.43
Net Sentiment
+$1.09M
Net buying
Most Active
Pangalos Menelas N
3 transactions
Analysis
Insiders reported 7 buys worth $1.22M and 2 sells worth $132,328.43 over the last 12 months. That adds up to net buying of $1.09M. Pangalos Menelas N was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +6.2% | +40.8% (7yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +6.2% over three years. Forward estimates point to Revenue at +40.8% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.37B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.38B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
MeiraGTx Holdings plc
NASDAQ:MGTX
$888.13M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Verastem, Inc.
NASDAQ:VSTM
$284.19M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages ABSI?
Absci Corporation (ABSI) lists 14 active executives. The top listed executive is Sean McClain, Founder, Chief Executive Officer, President & Director.
Are ABSI insiders buying or selling?
Recent insider activity shows net buying of $251.25M.
Explore More
Continue the stock analysis
Jump to another research area for this company.